|
|
OSUCCC
 |
Michael R. Grever, M.D.
Professor/ Chair
College of Medicine
Internal Medicine - Hematology/Oncology
215 Means Hall
1654 Upham Drive Columbus,OH. 43210
o |
(614) 293-8724 |
f |
(614) 293-6656 |
|
Programs
|
 |
|
|
Current Publications
|
|
Cancer Chemother Pharmacol in press: , 2009
|
|
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
|
|
Ramaswamy B, Bekaii-Saab T, Schaaf LJ, Lesinski GB, Lucas DM, Young DC, Ruppert AS, Byrd JC, Culler K, Wilkins D, Wright JJ, Grever MR, Shapiro CL
|
|
|
Pharm Res 26(6): 1504-15, 2009
|
|
A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels.
|
|
Chen P, Liu Z, Liu S, Xie Z, Aimiuwu J, Pang J, Klisovic R, Blum W, Grever MR, Marcucci G, Chan KK
|
|
|
Clin Cancer Res 15(18): 5895-901, 2009
|
|
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.
|
|
Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M
|
|
|
in press: , 2009
|
|
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.
|
|
Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, Lamb TA, Grever MR, Shapiro CL, Carson WE 3rd
|
|
|
in press: , 2009
|
|
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.
|
|
Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC
|
|
|
Leuk Lymphoma 50 Suppl 1: 1, 2009
|
|
Dedication to the clinical investigators for their work with hairy cell leukemia.
|
|
Grever MR
|
|
|
Clin Lymphoma Myeloma 9 Suppl 3: S179-85, 2009
|
|
Flavopiridol in chronic lymphocytic leukemia: a concise review.
|
|
Christian BA, Grever MR, Byrd JC, Lin TS
|
|
|
in press: , 2009
|
|
How I treat hairy cell leukemia.
|
|
Grever MR
|
|
|
Leuk Lymphoma 50 Suppl 1: 23-6, 2009
|
|
Long-term follow-up studies in hairy cell leukemia.
|
|
Grever MR, Zinzani PL
|
|
|
Blood 113(3): 535-7, 2009
|
|
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
|
|
Awan FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung N, Jelinek DF, Tschumper RC, Secreto CR, Lin TS, Grever MR, Shanafelt TD, Zent CS, Call TG, Heerema NA, Lozanski G, Byrd JC, Lucas DM
|
|
|
J Clin Oncol 27(31): 5270-7, 2009
|
|
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
|
|
Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, Chalupa D, Otterson GA, Shapiro CL, Fowler JM, Grever MR, Bekaii-Saab TS, Carson WE 3rd
|
|
|
J Clin Oncol in press: , 2009
|
|
Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease.
|
|
Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR, Byrd JC
|
|
|
J Clin Oncol 27(10): 1675-84, 2009
|
|
Phase II trial of sorafenib in metastatic thyroid cancer.
|
|
Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH
|
|
|
Leuk Res 33(11): 1475-80, 2009
|
|
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.
|
|
Farag SS, Zhang S, Jansak BS, Wang X, Kraut E, Chan K, Dancey JE, Grever MR
|
|
|
Br J Haematol 146(6): 660-4, 2009
|
|
Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia.
|
|
Shanafelt TD, Byrd JC, Laplant B, Zent CS, Call T, Secreto C, Grever MR, Lin TS, Kay NE
|
|
|
Blood 113(19): 4656-66, 2009
|
|
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.
|
|
Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, Goettl VM, Heerema NA, Lin TS, Lehman A, Zhang X, Jarjoura D, Newman DJ, Byrd JC, Kinghorn AD, Grever MR
|
|
|
Proteomics 9(5): 1197-206, 2009
|
|
Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia.
|
|
Su X, Lucas DM, Zhang L, Xu H, Zabrouskov V, Davis ME, Knapp AR, Young DC, Payne PR, Parthun MR, Marcucci G, Grever MR, Byrd JC, Freitas MA
|
|
|
Int J Pharm 365(1-2): 170-4, 2008
|
|
A novel liposomal formulation of flavopiridol.
|
|
Yang X, Zhao X, Phelps MA, Piao L, Rozewski DM, Liu Q, Lee LJ, Marcucci G, Grever MR, Byrd JC, Dalton JT, Lee RJ
|
|
|
Clin Cancer Res 14(11): 3434-40, 2008
|
|
A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors.
|
|
Bekaii-Saab TS, Liu J, Chan KK, Balcerzak SP, Ivy PS, Grever MR, Kraut EH
|
|
|
Blood 113(12): 2637-45, 2008
|
|
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
|
|
Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Booker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT
|
|
|
Cancer Biother Radiopharm 22(5): 713-4; author reply 715-7, 2008
|
|
Community-based phase II trial of PCR for CLL/SLL patients.
|
|
Kay NE, Shanafelt TD, Byrd JC, Grever MR
|
|
|
J Clin Oncol 25(35): 5624-9, 2008
|
|
Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.
|
|
Blum KA, Young DC, Broering S, Lucas MS, Fischer B, Lin TS, Grever MR, Byrd JC
|
|
|
Ther Drug Monit in press: Epub 2008, 2008
|
|
Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma.
|
|
Liu Q, Farley KL, Johnson AJ, Muthusamy N, Hofmeister CC, Blum KA, Schaaf LJ, Grever MR, Byrd JC, Dalton JT, Phelps MA
|
|
|
J Chromatogr B Analyt Technol Biomed Life Sci 871(1): 15-21, 2008
|
|
Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.
|
|
Johnston JS, Phelps MA, Blum KA, Blum W, Grever MR, Farley KL, Dalton JT
|
|
|
J Chromatogr B Analyt Technol Biomed Life Sci 868(1-2): 110-5, 2008
|
|
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule.
|
|
Phelps MA, Rozewski DM, Johnston JS, Farley KL, Albanese KA, Byrd JC, Lin TS, Grever MR, Dalton JT
|
|
|
Leuk Res 31(12): 1737-40, 2008
|
|
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.
|
|
Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC, Lucas DM
|
|
|
Blood 111(6): 3190-9, 2008
|
|
Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.
|
|
Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Dang VX, Viatchenko-Karpinski S, Ruppert AS, Byrd JC, Kuppusamy P, Crouser ED, Grever MR
|
|
|
Curr Opin Oncol 19(6): 573-8, 2008
|
|
Flavopiridol in the treatment of chronic lymphocytic leukemia.
|
|
Christian BA, Grever MR, Byrd JC, Lin TS
|
|
|
J Clin Endocrinol Metab 94(1): 164-70, 2008
|
|
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
|
|
Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, Grever M, Villalona-Calero M, Shah MH
|
|
|
Ann Oncol 19(11): 1903-9, 2008
|
|
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
|
|
Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D, Murgo AJ, Jensen R, Yeh TK, Wei Y, Zhang Y, Eng C, Grever M, Au JL, Villalona-Calero MA
|
|
|
Best Pract Res Clin Haematol 20(3): 545-56, 2008
|
|
Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.
|
|
Grever MR, Lucas DM, Johnson AJ, Byrd JC
|
|
|
J Clin Oncol 25(25): 3884-91, 2008
|
|
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
|
|
Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine S, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G
|
|
|
Clin Cancer Res 14(12): 3889-95, 2008
|
|
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
|
|
Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G
|
|
|
Blood 112(5): 1923-30, 2008
|
|
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
|
|
Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ
|
|
|
Br J Haematol 139(5): 837-44, 2008
|
|
Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
|
|
Johnson AJ, Wagner AJ, Cheney CM, Smith LL, Lucas DM, Guster SK, Grever MR, Lin TS, Byrd JC
|
|
|
